Search

Author/Creator Halfvarson, Jonas

31. Development of an index to define overall disease severity in IBD. Issue 2 (25th October 2016)

Authors:
Siegel, Corey A; Whitman, Cynthia B; Spiegel, Brennan M R; Feagan, Brian; Sands, Bruce; Loftus, Edward V; Panaccione, Remo; D'Haens, Geert; Bernstein, Charles N; Gearry, Richard; Ng, Siew C; Mantzaris, Gerassimos J; Sartor, Balfour; Silverberg, Mark S; Riddell, Robert; Koutroubakis, Ioannis E; O'...
Journal:
Gut
Issue:
Volume 67:Issue 2(2018)
Page Start:
244
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

33. Disease course of inflammatory bowel disease unclassified in a European population‐based inception cohort: An Epi‐IBD study. Issue 6 (21st January 2019)

Authors:
Burisch, Johan; Zammit, Stefania Chetcuti; Ellul, Pierre; Turcan, Svetlana; Duricova, Dana; Bortlik, Martin; Andersen, Karina Winther; Andersen, Vibeke; Kaimakliotis, Ioannis P; Fumery, Mathurin; Gower‐Rousseau, Corinne; Girardin, Giulia; Valpiani, Daniela; Goldis, Adrian; Brinar, Marko; Čuković‐...
Journal:
Journal of gastroenterology and hepatology
Issue:
Volume 34:Issue 6(2019)
Page Start:
996
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

34. Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers. Issue 4 (19th December 2020)

Authors:
Rundquist, Sara; Sachs, Michael C.; Eriksson, Carl; Olén, Ola; Montgomery, Scott; Halfvarson, Jonas
Other Names:
Andersson Marie investigator.; Bengtsson Jonas investigator.; Björk Jan investigator.; Eberhardson Michael investigator.; Fagerberg Ulrika L. investigator.; Grip Olof investigator.; Hjortswang Henrik investigator.; Jäghult Susanna investigator.; Karling Pontus investigator.; Ludvigsson Jonas F. i...
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 53:Issue 4(2021)
Page Start:
471
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

35. Editorial: infliximab or adalimumab as first‐ or second‐line anti‐TNF—conflicting evidence—authors' reply. Issue 6 (23rd August 2021)

Authors:
Visuri, Isabella; Eriksson, Carl; Olén, Ola; Cao, Yang; Mårdberg, Emelie; Grip, Olof; Gustavsson, Anders; Hjortswang, Henrik; Karling, Pontus; Montgomery, Scott; Myrelid, Pär; Ludvigsson, Jonas F.; Halfvarson, Jonas
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 54:Issue 6(2021)
Page Start:
848
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

36. Epigenetic alterations in inflammatory bowel disease: the complex interplay between genome-wide methylation alterations, germline variation, and gene expression. (23rd February 2017)

Authors:
Kalla, Rahul; Adams, Alex; Nimmo, Elaine; Kennedy, Nicholas; Ventham, Nicholas; Vatn, Morten; Jahnsen, Jorgen; Ricanek, Petr; Halfvarson, Jonas; Pierik, Marieke; Gomollon, Fernando; Gut, Ivo; D'Amato, Mauro; Satsangi, Jack
Journal:
Lancet
Issue:
Volume 389(2017)Supplement 1
Page Start:
S52
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

39. Genetic variants in CDC42 and NXPH1 as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome. Issue 7 (16th September 2013)

Authors:
Wouters, Mira M; Lambrechts, Diether; Knapp, Michael; Cleynen, Isabelle; Whorwell, Peter; Agréus, Lars; Dlugosz, Aldona; Schmidt, Peter Thelin; Halfvarson, Jonas; Simrén, Magnus; Ohlsson, Bodil; Karling, Pontus; Van Wanrooy, Sander; Mondelaers, Stéphanie; Vermeire, Severine; Lindberg, Greger; Spi...
Journal:
Gut
Issue:
Volume 63:Issue 7(2014)
Page Start:
1103
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗